Annual CFI
-$96.91 M
+$390.10 M+80.10%
31 December 2023
Summary:
Halozyme Therapeutics annual cash flow from investing activities is currently -$96.91 million, with the most recent change of +$390.10 million (+80.10%) on 31 December 2023. During the last 3 years, it has fallen by -$175.26 million (-223.68%). HALO annual CFI is now -223.68% below its all-time high of $78.35 million, reached on 31 December 2020.HALO Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$167.48 M
-$125.44 M-298.40%
30 September 2024
Summary:
Halozyme Therapeutics quarterly cash flow from investing activities is currently -$167.48 million, with the most recent change of -$125.44 million (-298.40%) on 30 September 2024. Over the past year, it has dropped by -$84.03 million (-100.70%). HALO quarterly CFI is now -386.58% below its all-time high of $58.44 million, reached on 31 December 2020.HALO Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$300.49 M
-$84.03 M-38.82%
30 September 2024
Summary:
Halozyme Therapeutics TTM cash flow from investing activities is currently -$300.49 million, with the most recent change of -$84.03 million (-38.82%) on 30 September 2024. Over the past year, it has dropped by -$210.13 million (-232.54%). HALO TTM CFI is now -334.62% below its all-time high of $128.08 million, reached on 30 September 2019.HALO TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +80.1% | -100.7% | -232.5% |
| 3 y3 years | -223.7% | -887.9% | -521.1% |
| 5 y5 years | -3987.2% | -508.5% | -334.6% |
HALO Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -223.7% | +80.1% | -404.6% | +61.5% | -3693.2% | +62.5% |
| 5 y | 5 years | -223.7% | +80.1% | -386.6% | +61.5% | -334.6% | +62.5% |
| alltime | all time | -223.7% | +80.1% | -386.6% | +61.5% | -334.6% | +62.5% |
Halozyme Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$167.48 M(+298.4%) | -$300.49 M(+38.8%) |
| June 2024 | - | -$42.04 M(-49.2%) | -$216.46 M(+81.2%) |
| Mar 2024 | - | -$82.68 M(+897.2%) | -$119.43 M(+23.2%) |
| Dec 2023 | -$96.91 M(-80.1%) | -$8.29 M(-90.1%) | -$96.91 M(+7.2%) |
| Sept 2023 | - | -$83.45 M(-251.7%) | -$90.36 M(+1040.7%) |
| June 2023 | - | $54.99 M(-191.4%) | -$7.92 M(-98.4%) |
| Mar 2023 | - | -$60.16 M(+3345.7%) | -$497.86 M(+2.2%) |
| Dec 2022 | -$487.00 M(+19.9%) | -$1.75 M(+73.2%) | -$487.00 M(-37.9%) |
| Sept 2022 | - | -$1.01 M(-99.8%) | -$784.73 M(-2.0%) |
| June 2022 | - | -$434.95 M(+782.2%) | -$800.67 M(+95.1%) |
| Mar 2022 | - | -$49.30 M(-83.5%) | -$410.34 M(+1.0%) |
| Dec 2021 | -$406.29 M(-618.5%) | -$299.47 M(+1666.4%) | -$406.29 M(+739.8%) |
| Sept 2021 | - | -$16.95 M(-62.0%) | -$48.38 M(-21.4%) |
| June 2021 | - | -$44.62 M(-1.4%) | -$61.52 M(+1129.2%) |
| Mar 2021 | - | -$45.25 M(-177.4%) | -$5.00 M(-106.4%) |
| Dec 2020 | $78.35 M(-1512.0%) | $58.44 M(-294.2%) | $78.35 M(-176.1%) |
| Sept 2020 | - | -$30.09 M(-352.9%) | -$102.91 M(+223.5%) |
| June 2020 | - | $11.90 M(-68.8%) | -$31.81 M(-949.0%) |
| Mar 2020 | - | $38.11 M(-131.0%) | $3.75 M(-167.5%) |
| Dec 2019 | -$5.55 M(-322.6%) | -$122.82 M(-399.6%) | -$5.55 M(-104.3%) |
| Sept 2019 | - | $41.00 M(-13.6%) | $128.08 M(+4.8%) |
| June 2019 | - | $47.46 M(+64.7%) | $122.27 M(+81.9%) |
| Mar 2019 | - | $28.81 M(+166.6%) | $67.21 M(+2595.8%) |
| Dec 2018 | $2.49 M(-101.5%) | $10.81 M(-69.3%) | $2.49 M(-101.6%) |
| Sept 2018 | - | $35.19 M(-562.6%) | -$157.30 M(-3.0%) |
| June 2018 | - | -$7.61 M(-78.8%) | -$162.21 M(-20.4%) |
| Mar 2018 | - | -$35.90 M(-75.9%) | -$203.90 M(+24.5%) |
| Dec 2017 | -$163.73 M(+113.3%) | -$148.99 M(-592.0%) | -$163.73 M(-2698.5%) |
| Sept 2017 | - | $30.28 M(-161.4%) | $6.30 M(-140.0%) |
| June 2017 | - | -$49.29 M(-1255.7%) | -$15.74 M(-147.5%) |
| Mar 2017 | - | $4.26 M(-79.7%) | $33.12 M(-143.1%) |
| Dec 2016 | -$76.77 M(-1403.8%) | $21.05 M(+155.2%) | -$76.77 M(-31.8%) |
| Sept 2016 | - | $8.25 M(-1995.6%) | -$112.57 M(+12.0%) |
| June 2016 | - | -$435.00 K(-99.6%) | -$100.52 M(+12.5%) |
| Mar 2016 | - | -$105.62 M(+615.8%) | -$89.31 M(-1616.9%) |
| Dec 2015 | $5.89 M(-117.9%) | -$14.76 M(-172.7%) | $5.89 M(-82.7%) |
| Sept 2015 | - | $20.29 M(+88.4%) | $34.13 M(+107.3%) |
| June 2015 | - | $10.77 M(-203.4%) | $16.46 M(-9245.0%) |
| Mar 2015 | - | -$10.42 M(-177.3%) | -$180.00 K(-99.5%) |
| Dec 2014 | -$32.95 M(-31.2%) | $13.48 M(+413.0%) | -$32.95 M(-25.8%) |
| Sept 2014 | - | $2.63 M(-144.8%) | -$44.42 M(-6.2%) |
| June 2014 | - | -$5.87 M(-86.4%) | -$47.37 M(+13.9%) |
| Mar 2014 | - | -$43.19 M(-2241.3%) | -$41.58 M(-13.1%) |
| Dec 2013 | -$47.87 M | $2.02 M(-720.6%) | -$47.87 M(-5.1%) |
| Sept 2013 | - | -$325.00 K(+306.3%) | -$50.43 M(+0.3%) |
| June 2013 | - | -$80.00 K(-99.8%) | -$50.27 M(-1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$49.48 M(+9066.5%) | -$50.91 M(+3503.0%) |
| Dec 2012 | -$1.41 M(+70.5%) | -$539.80 K(+222.3%) | -$1.41 M(-1.2%) |
| Sept 2012 | - | -$167.50 K(-76.8%) | -$1.43 M(+9.9%) |
| June 2012 | - | -$721.50 K(-4666.5%) | -$1.30 M(+113.5%) |
| Mar 2012 | - | $15.80 K(-102.8%) | -$609.70 K(-26.4%) |
| Dec 2011 | -$828.50 K(+28.2%) | -$557.00 K(+1328.2%) | -$828.50 K(+37.6%) |
| Sept 2011 | - | -$39.00 K(+32.2%) | -$602.20 K(-3.5%) |
| June 2011 | - | -$29.50 K(-85.5%) | -$623.80 K(-10.9%) |
| Mar 2011 | - | -$203.00 K(-38.6%) | -$700.40 K(+8.4%) |
| Dec 2010 | -$646.50 K(-55.7%) | -$330.70 K(+445.7%) | -$646.40 K(-26.5%) |
| Sept 2010 | - | -$60.60 K(-42.9%) | -$879.10 K(-9.3%) |
| June 2010 | - | -$106.10 K(-28.8%) | -$969.40 K(-24.9%) |
| Mar 2010 | - | -$149.00 K(-73.6%) | -$1.29 M(-11.6%) |
| Dec 2009 | -$1.46 M(+26.0%) | -$563.40 K(+273.4%) | -$1.46 M(+27.0%) |
| Sept 2009 | - | -$150.90 K(-64.7%) | -$1.15 M(-19.8%) |
| June 2009 | - | -$427.80 K(+34.1%) | -$1.43 M(+12.6%) |
| Mar 2009 | - | -$319.00 K(+26.4%) | -$1.27 M(+9.8%) |
| Dec 2008 | -$1.16 M(-51.0%) | -$252.40 K(-42.0%) | -$1.16 M(-40.2%) |
| Sept 2008 | - | -$435.40 K(+63.1%) | -$1.94 M(-0.1%) |
| June 2008 | - | -$267.00 K(+30.2%) | -$1.94 M(-19.4%) |
| Mar 2008 | - | -$205.00 K(-80.2%) | -$2.41 M(+1.9%) |
| Dec 2007 | -$2.37 M(+548.4%) | -$1.03 M(+136.6%) | -$2.37 M(+64.1%) |
| Sept 2007 | - | -$436.70 K(-40.5%) | -$1.44 M(+24.2%) |
| June 2007 | - | -$734.50 K(+356.5%) | -$1.16 M(+138.5%) |
| Mar 2007 | - | -$160.90 K(+47.2%) | -$486.80 K(+33.4%) |
| Dec 2006 | -$364.80 K(+4.0%) | -$109.30 K(-30.0%) | -$364.80 K(+38.8%) |
| Sept 2006 | - | -$156.20 K(+158.6%) | -$262.90 K(+29.3%) |
| June 2006 | - | -$60.40 K(+55.3%) | -$203.40 K(-21.5%) |
| Mar 2006 | - | -$38.90 K(+425.7%) | -$259.10 K(-26.2%) |
| Dec 2005 | -$350.90 K(+53.9%) | -$7400.00(-92.3%) | -$350.90 K(-23.6%) |
| Sept 2005 | - | -$96.70 K(-16.7%) | -$459.00 K(+18.9%) |
| June 2005 | - | -$116.10 K(-11.2%) | -$386.20 K(+22.0%) |
| Mar 2005 | - | -$130.70 K(+13.2%) | -$316.60 K(+38.9%) |
| Dec 2004 | -$228.00 K(<-9900.0%) | -$115.50 K(+383.3%) | -$227.90 K(+328.4%) |
| Sept 2004 | - | -$23.90 K(-48.6%) | -$53.20 K(+21.2%) |
| June 2004 | - | -$46.50 K(+10.7%) | -$43.90 K(+4.5%) |
| Mar 2004 | - | -$42.00 K(-170.9%) | -$42.00 K(<-9900.0%) |
| Dec 2003 | $0.00(0.0%) | $59.20 K(-505.5%) | $0.00(-100.0%) |
| Sept 2003 | - | -$14.60 K(-67.3%) | -$34.20 K(+74.5%) |
| June 2003 | - | -$44.60 K(<-9900.0%) | -$19.60 K(<-9900.0%) |
| Mar 2003 | - | $0.00(-100.0%) | $0.00(0.0%) |
| Dec 2002 | $0.00(0.0%) | $25.00 K(>+9900.0%) | $0.00(-100.0%) |
| Sept 2002 | - | $0.00(-100.0%) | -$25.00 K(0.0%) |
| June 2002 | - | -$25.00 K(<-9900.0%) | -$25.00 K(<-9900.0%) |
| Mar 2002 | - | $0.00 | $0.00 |
| Dec 2001 | $0.00 | - | - |
FAQ
- What is Halozyme Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual CFI year-on-year change?
- What is Halozyme Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly CFI year-on-year change?
- What is Halozyme Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM CFI year-on-year change?
What is Halozyme Therapeutics annual cash flow from investing activities?
The current annual CFI of HALO is -$96.91 M
What is the all time high annual CFI for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cash flow from investing activities is $78.35 M
What is Halozyme Therapeutics annual CFI year-on-year change?
Over the past year, HALO annual cash flow from investing activities has changed by +$390.10 M (+80.10%)
What is Halozyme Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of HALO is -$167.48 M
What is the all time high quarterly CFI for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cash flow from investing activities is $58.44 M
What is Halozyme Therapeutics quarterly CFI year-on-year change?
Over the past year, HALO quarterly cash flow from investing activities has changed by -$84.03 M (-100.70%)
What is Halozyme Therapeutics TTM cash flow from investing activities?
The current TTM CFI of HALO is -$300.49 M
What is the all time high TTM CFI for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM cash flow from investing activities is $128.08 M
What is Halozyme Therapeutics TTM CFI year-on-year change?
Over the past year, HALO TTM cash flow from investing activities has changed by -$210.13 M (-232.54%)